A Retired Drug Researcher's Journey Through Alzheimer's Diagnosis Highlights Gaps in Patient Access to Early Information
Key Insights
A retired drug researcher and pharmacist diagnosed with Alzheimer's argues that early diagnosis and accessible treatment information are critical for patient agency, countering the outdated belief that nothing can be done for the disease.
The patient's diagnostic journey involved self-directed research on ClinicalTrials.gov, enrollment in a Barrow Neurological Institute study using blood-based biomarkers and advanced imaging, which revealed high levels of disease-associated brain plaque.
After weighing risks and benefits of two recently approved therapies, the patient chose a treatment and reports feeling stable and clear-headed after 14 monthly infusions.
A retired drug researcher and pharmacy doctor who has become an Alzheimer's patient is calling for systemic changes in how the healthcare system approaches early diagnosis and patient education, arguing that the long-held belief that there is no point in pursuing an Alzheimer's diagnosis is no longer valid.
"Why pursue an Alzheimer's diagnosis if there's nothing effective to treat it? This common refrain is no longer true," the patient-researcher writes in a first-person commentary. "I want patients to be armed with information so they can make informed care decisions about how they want to live. Patients need access to early diagnosis and clear, accessible information about their treatment options and risks."
A Self-Directed Path to Diagnosis
The journey began when the author noticed concerning changes: sudden lapses in awareness, decreased muscle tone, and unexplained weight loss. When a primary care physician attributed these symptoms to aging, the patient — drawing on a professional background in drug development and clinical research — trusted personal instincts and family history, which includes both dementia and a brain tumor.
Understanding that current Alzheimer's treatments "may help manage symptoms or slow progression, but they do not cure Alzheimer's," the author took an unconventional route. Searching ClinicalTrials.gov independently, the patient connected with the Barrow Neurological Institute in Phoenix and gained acceptance into a diagnostic study.
The study enrolled a wide spectrum of participants, from cognitively normal individuals to those with dementia, and deployed a battery of advanced cognitive and diagnostic tools. These included blood-based biomarkers — holding the potential to diagnose Alzheimer's through a blood test — and imaging techniques, many of which remain under validation. Notably, participation came at no cost to the patient.
The tests ultimately provided clarity: they revealed a high level of disease-associated plaque in the brain, confirming an Alzheimer's diagnosis.
Treatment Decisions and Outcomes
Armed with diagnostic certainty, the patient researched two recently approved therapies, carefully weighing risks, benefits, and alignment with personal priorities. The stated goal was "to live the rest of my life with quality and dignity, not simply to extend it at all costs."
After selecting a treatment compatible with both lifestyle and risk tolerance, the patient completed 14 monthly infusions and now reports feeling "stable, clear-headed and motivated to help others navigate this disease."
Systemic Barriers to Patient Agency
Despite this positive personal outcome, the commentary highlights persistent structural failures. "Too many Californians don't have access to this kind of clarity or choice," the author states, identifying four key areas requiring reform.
First, the perception of Alzheimer's as an inevitable end-of-life process must be dispelled. The author emphasizes that Alzheimer's is "a disease, one that deserves earlier attention, better tools and more proactive care."
Second, patients require assistance navigating their options, including finding clinical trials, understanding diagnostic tools, and managing the financial realities of care. The commentary notes that "many promising diagnostic tests are not consistently covered by insurance, putting answers out of reach for those who need them most."
Third, industry must improve patient communication by developing "clear, accessible materials that explain clinical trials, risks and benefits to help patients make informed decisions."
Finally, the author calls for broader societal understanding of Alzheimer's true cost — "not just medical, but economic and human" — and argues that better data on patient preferences, outcomes, and societal costs can help prioritize effective solutions.
The patient-researcher continues to live intentionally, staying active, challenging the mind, and spending time with family, including seven grandchildren. "My career in research may look different today, but I am still contributing, now as both a patient and an advocate," the author concludes. "Alzheimer's is not easy. But with the right information, support and mindset, it is still possible for Californians to face it with clarity and to live well in the time we have."